Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies orders, deals and press releases
51 filed, newest first. Page 1 of 2.
Nov 2024
Mar 2024
Dec 2023
Nov 2023
Oct 2023
Sep 2023
Aug 2023
Jul 2023
Jun 2023
May 2023
Apr 2023
Mar 2023
Feb 2023
Apr 2022
Jan 2022
Dec 2021
Jul 2021
May 2021
Apr 2021
Nov 2020
6 Nov · Business
Jan 2018
Sep 2017
Aug 2017
Apr 2017
Feb 2017
Aug 2012
Feb 2012
27 Feb · Business
Board of Directors of the Company at its meeting held on February 27, 2012 inter alia approved allotment of 6,00,000 equity shares of Rs.10 each to promoter group company pursuant to conversion of warrants fully convertible into equity shares.
Dec 2010
20 Dec · Business
Board of Directors have in it's meeting held on December 18, 2010 has inter alia approved allotment of 37,137 equity shares of Rs. 10/- each pursuant to request for partly conversion of Foreign Currency Convertible Bonds by FCCB holders, out of US$ 5 million bonds rollover till 2015.
Nov 2010
Oct 2010
18 Oct · Business
Board of Directors at its meeting held on October 15, 2010 transacted the following business: 1) Allotted 12,00,000 warrants fully convertible into equity shares to Sunev Pharma Solutions Limited a promoter group company on preferential basis.
Aug 2010
24 Aug · Business
Board of Directors in its Meeting held on August 24, 2010 has inter alia approved issue of Fully Convertible warrants on a preferential basis to Sunev Pharma Solutions Ltd. a promoter group company upto 5% of the total capital in accordance with SEBI ( Substantial Acquisitions and Takeovers) Regulations, 1997. The same is also subject to applicable provisions of SEBI/Companies Act and approval of shareholders at the forthcoming Annual General Meeting.